OPINION Inherited disorders of calcium and phosphate metabolism
INTRODUCTION
Calcium and phosphate play a critical role in many biological functions and are essential components of bone. Regulation of calcium and phosphate homeostasis is tightly controlled with complex interaction between bone, intestine, and kidney. The kidney ultimately regulates serum levels of calcium and phosphate by regulating their transport and urinary losses. Serum calcium and phosphate levels that are routinely measured in clinical practice are not a true reflection of their total body stores as a very small proportion (<1%) of total body stores are present in the serum. While adults are in neutral phosphate and calcium balance, children are in positive calcium and phosphate balance due to growth. There are multiple inherited disorders of calcium and phosphate metabolism resulting in a wide range of symptoms which can be challenging to the clinician. In addition, there are nutritional causes for disturbances of calcium and phosphate homeostasis. For the purpose of this review, we will primarily focus on the inherited disturbances of calcium and phosphate homeostasis, their mode of inheritance, clinical presentation, and therapeutic options.
Calcium is absorbed from the gastrointestinal tract (duodenum and early jejunum) both via nonsaturable paracellular pathway and a 1,25-vitamin D 3 -regulated saturable and active transcellular pathway [2, 3] . Serum calcium levels range from 8.5 to 10.5 mg/dl (2.1-2.6 mmol/l). Serum ionized calcium, the physiological active form of calcium is maintained in a narrow range due to its critical functions. Blood calcium exists in three forms; approximately 45% is protein-bound, 45% is free, and approximately 10% is complexed to citrate, sulfate, bicarbonate, and phosphate. Both complexed and free calcium are filtered across the glomerulus [4] . Of the filtered calcium, about 1% is excreted in urine underscoring the remarkable capacity of the kidney to reabsorb calcium [5] . Approximately 65-70% of filtered calcium is reabsorbed in the proximal tubule via the paracellular route in an iso-osmotic and passive fashion [5] [6] [7] . Approximately 20% of filtered calcium is reabsorbed in the thick ascending limb of the Henle across the paracellular pathway; the driving force for this process is the lumen-positive potential difference in this segment. Finally, 10-15% of filtered calcium is reabsorbed in the distal convoluted tubule and connecting tubule in which calcium reabsorption is active, transcellular and tightly regulated. The transient receptor potential vanilloid five (TRPV5) channel is primarily responsible for calcium uptake in the distal tubular cells; intracellular calcium is bound to calbindin-D28K and is transported to the basolateral membrane where calcium exits to the intravascular space by two transporters: sodium/calcium exchanger 1 (NCX1) and plasma membrane calcium ATPase isoform 1b (PMCA1b) [8] .
Regulation of calcium homeostasis involves two important hormones: parathyroid hormone (PTH) and 1,25-vitamin D 3 . The parathyroid gland senses serum ionized calcium levels through calcium-sensing receptor (CaSR), and regulates PTH synthesis and secretion [9] . Low ionized calcium inactivates CaSR and stimulates PTH secretion, whereas high calcium levels activate the receptor which results in decreased PTH secretion. PTH regulates calcium homeostasis via activating the PTH receptor which increases active reabsorption of calcium in the kidney. PTH activates osteoclastic bone resorption through the receptor activator of nuclear factor kB ligand (RANKL), osteoprotegerin, and RANK system [10] . PTH stimulates 1a-hydroxylase in the proximal tubule, the enzyme responsible for conversion of 25-vitamin D to 1,25-vitamin D 3 , which increases calcium absorption from the gastrointestinal tract and kidney by increasing the expression of transcellular calcium transport machinery [11, 12] . 1,25-vitamin D 3 also stimulates bone resorption. Dietary calcium also plays an important role in regulating calcium homeostasis as seen in mice with the absence of either the vitamin D receptor (VDR) or 1a-hydroxylase. In these mice, an increase in calcium intake increases calcium absorption in both the intestine and kidney which increases serum calcium levels [11] [12] [13] .
HYPOCALCEMIA
Hypocalcemia can affect many organ systems and causes arrhythmias, prolongation of QTc interval on the electrocardiogram (ECG), hypotension, coarse hair, dry skin, muscle twitching and tingling, paresthesias, tetany, and seizures. Trousseau's and Chvostek's signs are used to examine for increased neuromuscular activity. Chvostek's sign is noted by contraction of facial muscles by tapping on the facial nerve near the temporomandibular joint, and Trousseau's sign is elicited by inflating the blood pressure (BP) cuff above the patient's SBP for 3 min, which results in spasm of the involved hand. The inherited causes of hypocalcemia can be broadly classified in to disorders of vitamin D metabolism, CaSR, and parathyroid gland. These conditions are outlined in Table 1 
KEY POINTS
Calcium and phosphate homeostasis is tightly regulated due to their vital role in many biological processes.
Inherited disorders of calcium metabolism are primarily due to abnormalities of PTH and its receptors, vitamin D metabolism and CaSR.
Inherited disorders of phosphate metabolism are primarily due to abnormalities of FGF23, PTH, sodium phosphate transporters and Klotho.
absence/hypoplasia of thymus, and cardiac and craniofacial defects due to deletion of 22q11.2 in most patients. Hypocalcemia is usually noted in 50-60% of the neonates and can be transient, but hypocalcemia can also present for the first time in adulthood [16, 17] .
Autosomal dominant hypercalciuric hypocalcemia
Autosomal dominant hypercalciuric hypocalcemia (ADHH) or familial benign hypercalciuric hypocalcemia (FBHH) is due to gain-of-function mutation of CaSR resulting in a higher serum calcium threshold necessary for PTH secretion. Patients have mild hypocalcemia, inappropriately normal or low PTH levels, hypomagnesemia, and hypercalciuria, and are usually asymptomatic. If asymptomatic patients are treated with calcium and 1,25-vitamin D 3 supplements, the hypercalciuria can worsen and result in nephrocalcinosis. The aim is not to normalize calcium, but to keep the patients asymptomatic with minimal dose of supplements [18, 19] .
Pseudohypoparathyroidism
Pseudohypoparathyroidism type Ia (PHP-Ia), known as Albright's hereditary osteodystrophy, is characterized by hypocalcemia, hyperphosphatemia, and elevated PTH levels due to resistance to PTH. It is inherited in an autosomal dominant fashion and results from mutations in the GNAS1 gene which encodes for G s a subunit (G protein alpha subunit). G s a is a subunit of G s protein which stimulates cyclic adenosine monophosphate (cAMP) production by several hormones including PTH, thyrotropin, and gonadotropin-releasing hormone [20, 21] . Clinical features include obesity, short stature, brachydactyly, ectopic calcifications, developmental delay, and multiple endocrine deficiencies. PseudoPHP (pPHP) is also an autosomal dominant condition that has similar physical presentation as PHP-Ia, but lacks other endocrine deficiencies. Patients with both PHP-Ia and pPHP can be found in the same extended family due to parental imprinting of hormone resistance. Patients with PHP-Ia have inherited the mutated gene from their affected mother with either PHP-Ia or pPHP, and patients with pPHP have inherited the mutation from their father [22, 23] . PHP type Ib (PHP-Ib) is characterized by PTH resistance and is caused by loss of methylation with in GNAS1 on the maternal allele. The clinical features include hypocalcemia and hyperphosphatemia, and some of these patients have also shown resistance to thyrotropin and have shortened fourth metacarpal [24, 25] . Therapy involves calcium and 1,25-vitamin D 3 supplements while monitoring for hypercalciuria and nephrocalcinosis.
Vitamin D-dependent (resistant) rickets
Vitamin D is either produced in the skin or is ingested in the diet. Vitamin D is hydroxylated in the liver by 25-hydroxylase to 25-vitamin D, the most abundant circulatory form of vitamin D. It is further hydroxylated by 1a-hydroxylase to 1,25-vitamin D 3 , the active form of vitamin D, and 1a-hydroxylase is tightly regulated by PTH, fibroblast growth factor 23 (FGF23), calcium, phosphate, and by 1,25-vitamin D 3 itself. Vitamin D-dependent rickets type 1 (pseudovitamin D-deficiency rickets) is due to mutations in the 1a-hydroxylase gene, resulting in either absence or decreased function of 1a-hydroxylase activity, and is inherited in an autosomal recessive fashion.
Patients usually present at few months after birth to 2 years of age with seizures, hypotonia growth delay, and signs of rickets (prominent forehead, rachitic rosary, enlarged wrists and ankles). Evaluation reveals hypocalcemia, hypophosphatemia, elevated levels of PTH and alkaline phosphatase, and very low 1,25-vitamin D 3 levels. 25-vitamin D levels are usually normal in these patients. Treatment is with 1,25-vitamin D 3 supplementation [26, 27] . Vitamin D-dependent rickets type 2 (vitamin D-resistant rickets) is due to mutation in the VDR and is inherited in an autosomal recessive manner with heterogeneous presentation. Patients usually present within months after birth with rickets. Biochemical abnormalities are similar to vitamin D-dependent rickets type 1 except that 1,25-vitamin D 3 levels are elevated. Another unique feature that is seen in these patients is alopecia totalis. Treatment in these patients can be challenging; however, some patients do respond to high doses of 1,25-vitamin D 3 or its analogs. Patients who do not respond can be treated with oral and intravenous calcium salts with limited success [28, 29] .
HYPERCALCEMIA
The symptoms of hypercalcemia are dependent not only on the severity of hypercalcemia but also the rate of rise in serum calcium levels. The spectrum of symptoms includes four mains organ systems: renal, gastrointestinal, neurological, and cardiac. Patients can present with constipation, loss of appetite, weight loss, abdominal pain, acute pancreatitis, vomiting, irritability, poor concentrating capacity, memory loss, muscle weakness, lethargy, hypertension, shortened QTc interval, and cardiac arrhythmias. Renal symptoms include polyuria, polydipsia, volume depletion, nephrocalcinosis, and renal failure. The inherited disorders of hypercalcemia can be broadly classified into disorders of parathyroid gland, CaSR, and PTH receptor, and are shown in 
Idiopathic hypercalcemia of infancy (Lightwood syndrome)
Hypercalcemia is noted in these patients between 6 and 12 months of age. Other features of Lightwood syndrome are failure to thrive, vomiting, dehydration, hypercalciuria, and nephrocalcinosis. Patients usually do not exhibit any dysmorphic features and lack cardiac anomalies. PTH levels are commonly suppressed with upper limits of normal to elevated 25-vitamin D 3 and 1,25-vitamin D 3 . Recently, mutations of 24-hydroxylase gene have been noted in these patients and the inheritance appears to be autosomal recessive. This mutation when present will therefore predispose children to develop hypercalcemia when supplemented with vitamin D. Even though Lightwood syndrome is rare, it is important for physicians to be aware of this condition due to the increasing use of vitamin D supplementation in healthy children and adults [35,36,37 && ].
Jansen's metaphyseal chondrodysplasia
Jansen's metaphyseal chondrodysplasia is due to constitutive activation of the PTH receptor resulting in hypercalcemia, hypophosphatemia, and abnormal chondrocyte proliferation, and is inherited in an autosomal dominant manner. Patients have short stature with short extremities with normal PTH and PTH-related peptide levels [38] .
PHOSPHATE HOMEOSTASIS
Phosphate plays a vital role in many physiological functions including cell structure, energy metabolism, oxygen transport, intracellular signaling, and as a urinary and serum buffer. Phosphate is also an important component of the skeletal system. An average adult has approximately 700 g of phosphate and the majority of which (85%) is in the skeleton with approximately 1% in the extracellular fluid. Inorganic free phosphorus (phosphate) is measured by the laboratories and normal values are in the range of 3-4.5 mg/dl (1-1.5 mmol/l). Small portion of serum phosphate (10%) is protein-bound. Neonates are in positive phosphate balance due to their increased needs for skeletal development. Phosphate is absorbed from the gastrointestinal tract via a paracellular, nonsaturable process and an active transcellular pathway via the sodium phosphate cotransporter 2b (NaPi2b). NaPi2b is regulated by dietary phosphate, metabolic acidosis, and 1,25-vitamin D 3 . After phosphate reaches the circulation, free and complexed phosphate is filtered and approximately 80-90% is reabsorbed by the kidney primarily via two transporters on the apical membrane of the proximal tubule, designated as NaPi2a and NaPi2c. Phosphate homeostasis is primarily regulated by dietary phosphate, 1,25-vitamin D 3 , PTH, FGF23, and Klotho.
Parathyroid hormone, though primarily a calcium regulatory hormone, inhibits renal phosphate reabsorption causing urinary phosphate wasting by decreasing the expression of NaPi2a and NaPi2c. PTH increases the synthesis of 1,25-vitamin D 3 in the proximal tubule which in turn increases gastrointestinal absorption of phosphate via NaPi2b. Low dietary phosphate decreases and high dietary phosphate increases renal phosphate excretion. FGF23 increases renal phosphate wasting by inhibiting NaPi2a and NaPi2c in the proximal tubule. Additionally, FGF23 decreases expression of 1a-hydroxylase and increases expression of 24 hydroxylase with the net result of lower 1,25-vitamin D 3 levels [39, 40] . Klotho is an essential coreceptor for FGF23, but Klotho independently has also been shown to cause renal phosphate wasting [41] .
HYPOPHOSPHATEMIA
The acute symptoms of hypophosphatemia include myopathy, fatigue, bone pain, increased risk for rhabdomyolysis, and hemolysis. Respiratory and cardiac failure can occur with hypophosphatemia. Chronic hypophosphatemia results in skeletal abnormalities including rickets and osteomalacia. Inherited hypophosphatemic conditions can be classified in to FGF23-dependent and FGF23-independent disorders and are outlined in Table 1 .
Syndromes of fibroblast growth factor 23 excess
Autosomal dominant hypophosphatemic rickets (ADHR) is characterized by phosphaturia, hypophosphatemia and inappropriately normal or low 1,25-vitamin D 3 . Patients also can have dental dysplasia and enthesopathies (painful mineral deposits at the site of tendon insertion). Serum calcium and PTH levels are usually normal. ADHR is due to mutation of the FGF23 protein at the arginine residues either at 176 or 179 position (R 176 XXR 179 ), making it resistance to cleavage by proteases. FGF23 levels are thus elevated in these patients. ADHR has a variable penetrance even within the same family. ADHR has dichotomous presentation: adolescence/ adulthood (group 1) or childhood (group 2). Group 1 presents with muscle weakness, bone pain, and fractures, but with no bone deformities, whereas group 2 presents with rickets and bone deformities. In many of the group 1 patients, pregnancy was a precipitating factor for their presentation. In some patients with childhood presentation, renal phosphate wasting resolves after puberty [42] . Treatment options include phosphate supplements and calcitriol.
X-linked hypophosphatemic rickets (XLH) is the most common (1 : 20 000) inherited form of rickets and is inherited in an X-linked dominant manner. XLH is due to mutation in the PHEX (phosphateregulating gene with homologies to endopeptidases on the X-chromosome) gene. It is unclear as to how mutations of the PHEX gene result in elevated serum FGF23 levels. Males and females are affected and their clinical presentation is similar to patients with ADHR. Additional features include short stature, frontal bossing, and craniosynostosis. Treatment options include phosphate supplements and calcitriol which improves symptoms but does not normalize serum phosphate levels [43,44,45 & ]. Treatment complications include hypercalciuria, nephrocalcinosis, and secondary hyperparathyroidism. Cinacalcet can be used to treat secondary hyperparathyroidism [46] . Future treatment options include FGF23-neutralizing antibodies which have shown improvement in hypophosphatemia and rickets when used in a mouse model of XLH (Hyp mouse) [47, 48] .
Autosomal recessive hypophosphatemic rickets (ARHR) is a rare disease which is due to inactivating homozygous mutations of dentin matrix protein 1 (DMP1) or ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) genes. Patients with ARHR have inappropriately normal or elevated levels of FGF23 and it is yet unknown how DMP1/ENPP1 mutations cause elevated FGF23 levels. Clinical presentation and treatment options are similar to ADHR and XLH [49] [50] [51] .
Fibrous dysplasia is characterized by fibrous skeletal lesions which exist in two forms: monostotic and polyostotic. McCune Albright syndrome is due to activating mutations of GNAS-1 which encodes for G s a subunit and is characterized by Café-au-lait spots, precocious puberty and polyostotic fibrous dysplasia. Some of these fibrous dysplasia lesions can secrete FGF23 which causes a phenotype similar to XLH, ARHR, and ADHR. It is unknown as to why these fibrous lesions produce FGF23 when GNAS-1 is mutated. Treatment is symptomatic with phosphate supplements, calcitriol, and recently bisphosphonates has been used with some success [52, 53] .
Translocation of the Klotho gene resulting in increased Klotho levels has been described in one patient causing hypophosphatemia, hyperparathyroidism needing parathyroidectomy, hypercalcemia, and inappropriately normal 1,25-vitamin D 3 levels [54] .
Fibroblast growth factor 23-independent hypophosphatemic disorders
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is an autosomal recessive disease and is due to mutations of NaPi2c. Patients present with bone pain, weakness, fractures, short stature, and rickets. Patients have hypophosphatemia, phosphaturia, hypercalciuria, elevated 1,25-vitamin D 3 , and low PTH levels. Hypophosphatemia is potent stimulus for 1a-hydroxylase, which increases serum 1,25-vitamin D 3 levels, which in turn increases gastrointestinal absorption of calcium and phosphate and decreases PTH levels. In the face of suppressed PTH levels, patients develop hypercalciuria with the risk of developing nephrocalcinosis and decreased bone mineral density. Treatment is primarily with phosphate supplements. Treatment with calcitriol will worsen hypercalciuria and should not be used [55, 56] . NaPi2a mutations unlike NaPi2c result in autosomal recessive Fanconi syndrome. The reason for the difference in presentation when the different proximal tubule phosphate transporters are mutated is not clear [57] .
Inherited forms of primary hyperparathyroidism, activating mutations of PTH receptor, vitamin D-dependent rickets types 1 and 2 can also present with hypophosphatemia and are described in the hypocalcemia section.
HYPERPHOSPHATEMIA
The acute symptoms of hyperphosphatemia are primarily due to the resulting hypocalcemia and its symptoms [58] . An acute phosphate load especially after phosphate enemas has been shown to cause phosphate nephropathy and acute kidney injury [59] . Chronic hyperphosphatemia has been associated with vascular calcifications, especially in patients with chronic kidney disease and end-stage renal disease [60] . Inherited hyperphosphatemic conditions can be classified in to FGF23-dependent and FGF23-independent disorders. These are outlined in Table 1 .
Fibroblast growth factor 23 deficiency disorders
Familial tumoral calcinosis is primarily inherited as an autosomal recessive disorder with hyperphosphatemia, hypercalcemia, elevated or inappropriately normal levels of 1,25-vitamin D 3 and ectopic calcifications which can be painful. Serum calcium and PTH levels are usually normal. Two mutations have been identified: GALNT3 and FGF23 genes. GALNT3 encodes for UDP-N-acetyl-alpha-D-galactosamine:polypeptide-N -acetylgalactosaminyl transferase 3 which glycosylates threonine 178 , at the cleavage site, R 176 XXR 179 of FGF23. The resultant mutant FGF23 protein is prone to increased degradation by proteases. Inactivating mutations of the FGF23 gene results in mutant FGF23 which is either not secreted in its intact form or is cleaved faster by proteases. In both of the mutations, the intact FGF23 levels are low, whereas C-terminal FGF23 levels are elevated [61, 62] .
Fibroblast growth factor independent hyperphosphatemic disorders
Phenotype similar to tumoral calcinosis was seen in a 13-year-old patient who was found to have a homozygous missense mutation of the Klotho gene. However, the patient was noted to have elevated both intact and C-terminal FGF23 levels. In-vitro studies demonstrated that the mutant Klotho protein was less stable and had lower expression [63] . As Klotho is an essential coreceptor for FGF23, mutation of the Klotho protein causes resistance to FGF23 and thus resulting in a phenotype similar to FGF23 deficiency.
Inherited causes of hypoparathyroidism and PHP are described in the hypocalcemia section.
CONCLUSION
Inherited disorders of calcium and phosphate homeostasis have variable presentation. The primary organs involved in calcium and phosphate metabolism are the kidney, bone, parathyroid gland, and the gastrointestinal tract. The hormones involved are PTH, FGF23, Klotho, and 1,25-vitamin D 3 . Careful stepwise evaluation of these organ systems and hormones will greatly aid in the diagnostic process. Identifying the exact defect in these disorders will guide treatment options. Importantly, genetic counseling should be provided to the affected families.
